Potential Role of Bioactive Lipids in Rheumatoid Arthritis

(E-pub Ahead of Print)

Author(s): Wheeler Torres*, Mervin Chávez-Castillo, José L. Peréz-Vicuña, Rubén Carrasquero, María P. Díaz, Yosselin Gomez, Paola Ramírez, Clímaco Cano, Joselyn Rojas-Quintero, Maricarmen Chacín, Manuel Velasco, Juan Bautista de Sanctis, Valmore Bermudez

Journal Name: Current Pharmaceutical Design

Become EABM
Become Reviewer
Call for Editor


Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that involves a pathological inflammatory response against articular cartilage in multiple joints throughout the body. It is a complex disorder associated with comorbidities such as depression, lymphoma, osteoporosis, and cardiovascular disease (CVD), which significantly deteriorate patients’ quality of life and prognosis. This has ignited a large initiative to elucidate the physiopathology of RA, aiming to identify new therapeutic targets and approaches in its multidisciplinary management. Recently, various lipid bioactive products have been proposed to have an essential role in this process, including eicosanoids, specialized pro-resolving mediators, phospholipids/sphingolipids, and endocannabinoids. Dietary interventions using omega-3 polyunsaturated fatty acids or treatment with synthetic endocannabinoid agonists have been shown to significantly ameliorate RA symptoms. Indeed, the modulation of lipid metabolism may be crucial in the pathophysiology and treatment of autoimmune diseases.

Keywords: Rheumatoid arthritis, inflammation, bioactive lipids, resolving, autoimmune disease, cardiovascular disease.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 25 May, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1381612827666210525164734
Price: $95

Article Metrics

PDF: 11